News
2018 Precision Medicine World Conference to Feature UCSF Faculty
For the third consecutive year, UC San Francisco is co-sponsoring the Precision Medicine World Conference (PMWC) in January 2018 to share the latest in the rapidly evolving space. Renamed from the Personalized Medicine World Conference, the annual forum attracts more than 1,000 recognized
Year in Review: 2017
2017 has been a year of collaboration, innovation, and achievement at the Helen Diller Family Comprehensive Cancer. As the year winds down, we take a moment to reflect on some highlights. Our dedicated clinicians, curious researchers, and inspired philanthropists joined forces with patients and
Collaboration Highlights UCSF Cancer Center's Leadership in Precision Medicine for Prostate Cancer
A new collaboration between the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) and the biotechnology company Strata Oncology to provide free genomic testing to men with advanced prostate cancer could help patients nationwide gain access to cutting-edge treatment and lead to new
New Immunotherapy for Deadly Childhood Brain Cancer Targets Novel "Neoantigen"
Children with an extremely deadly form of brain cancer might benefit from a new treatment that aims to direct an immune response against a mutant form of a protein found exclusively on cancer cells, according to a new study led by UC San Francisco researchers. The focus of the study, published
Biochemist Peter Walter Receives 2018 Breakthrough Prize in Life Sciences
Peter Walter, PhD, professor of biochemistry and biophysics at UC San Francisco, has been named winner of a 2018 Breakthrough Prize in Life Sciences, for his research on a biological mechanism that normally protects cells, but can cause disease if not functioning properly. The Breakthrough Prizes
Sugar Industry Suppressed Evidence of Health Risks of Sucrose
The sugar industry buried scientific research almost 50 years ago that pointed to negative health effects of sugar, ceasing funding the research when it reflected negatively on the industry's interests, according to a new UC San Francisco study. In a study to be published Nov. 21, 2017 in PLOS
HDFCCC Global Cancer Team Visits Tanzanian Partners
In September, Katherine Van Loon, MD, MPH, assistant professor in hematology/oncology and director of the HDFCCC Global Cancer Program, led a group of UCSF faculty and trainees to Tanzania to meet with stakeholders at the Muhimbili University of Health and Allied Sciences (MUHAS) and Ocean Road